How to innovate and influence people in times of misinformation
January 11, 2022 | patient engagement
The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the right approach to help companies with breakthrough innovations in their pipeline build consumer confidence.
Rewind to late 2019. If you had been told that within a few months, you’d be living in the middle of the biggest pandemic since the 1918 global flu outbreak, but that thanks to new mRNA technology, vaccine prototypes would be ready for trials within weeks and the first shots would go into arms before the end of 2020, what would you have thought?
You could be forgiven for assuming that people would marvel in unison about the miracle of modern medical science. Alas, it didn’t quite go that way.
While most people were relieved to be able to get their shots so soon, a significant section of society went the opposite way and refused to get vaccinated. Some were simply hesitant because they lacked information. A good portion of that group has come around by now. But in the end, the refusal camp was strong enough to hamstring the U.S. vaccination effort, which left us more vulnerable to Delta-driven COVID surges in the summer and fall of 2021, as well as the Omicron variant that showed up toward the end of the year.
Considering what else is in the technology pipeline, that should give us all pause. If the medical sector can’t get a handle on the growing public trust disconnect, it will mean significant dollars lost. But it will also mean that breakthrough innovations will fail to make their full positive impact, which would ultimately create significant adverse public health impacts.
Read the full article on the Stonearch Creative website
This content was provided by Avalere Health
Company Details
Latest Content from Avalere Health
Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs
Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.
Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient
As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.
Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities
As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.
Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies
Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the…
Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer
Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts…
The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of…
Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech…
Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.